Chartwell Investment Partners LLC lowered its position in shares of Haemonetics Corporation (NYSE:HAE) by 2.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 337,013 shares of the medical instruments supplier’s stock after selling 8,868 shares during the quarter. Chartwell Investment Partners LLC owned 0.64% of Haemonetics Corporation worth $15,121,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of HAE. Victory Capital Management Inc. grew its stake in shares of Haemonetics Corporation by 18.7% during the 3rd quarter. Victory Capital Management Inc. now owns 2,414,526 shares of the medical instruments supplier’s stock worth $108,340,000 after purchasing an additional 381,012 shares during the period. HealthCor Management L.P. grew its stake in Haemonetics Corporation by 15.9% in the 2nd quarter. HealthCor Management L.P. now owns 1,854,872 shares of the medical instruments supplier’s stock valued at $73,249,000 after acquiring an additional 254,872 shares during the last quarter. Wells Fargo & Company MN grew its stake in Haemonetics Corporation by 9.3% in the 2nd quarter. Wells Fargo & Company MN now owns 2,788,122 shares of the medical instruments supplier’s stock valued at $110,104,000 after acquiring an additional 238,294 shares during the last quarter. Anchor Capital Advisors LLC grew its stake in Haemonetics Corporation by 41.7% in the 2nd quarter. Anchor Capital Advisors LLC now owns 774,906 shares of the medical instruments supplier’s stock valued at $30,601,000 after acquiring an additional 227,941 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Haemonetics Corporation in the 2nd quarter valued at about $6,115,000.

COPYRIGHT VIOLATION NOTICE: “Chartwell Investment Partners LLC Has $15.12 Million Holdings in Haemonetics Corporation (HAE)” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/chartwell-investment-partners-llc-has-15-12-million-holdings-in-haemonetics-corporation-hae/1717886.html.

A number of equities research analysts recently commented on HAE shares. TheStreet raised shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a research note on Monday, August 7th. Jefferies Group LLC reissued a “buy” rating and issued a $48.00 price objective on shares of Haemonetics Corporation in a research note on Thursday, July 27th. Zacks Investment Research raised shares of Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Wednesday, August 9th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $43.00 price objective (up from $38.00) on shares of Haemonetics Corporation in a research note on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. Haemonetics Corporation presently has an average rating of “Hold” and an average price target of $53.33.

In other news, CFO Willaim P. Burke sold 13,193 shares of the stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $54.04, for a total transaction of $712,949.72. Following the transaction, the chief financial officer now directly owns 27,227 shares in the company, valued at approximately $1,471,347.08. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Dan Goldstein sold 4,691 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $54.93, for a total transaction of $257,676.63. Following the transaction, the chief accounting officer now owns 3,747 shares in the company, valued at $205,822.71. The disclosure for this sale can be found here. Insiders have sold a total of 40,250 shares of company stock worth $2,196,240 over the last ninety days. 1.20% of the stock is owned by corporate insiders.

Haemonetics Corporation (NYSE:HAE) traded down $0.29 during trading on Tuesday, hitting $57.70. 613,600 shares of the company’s stock traded hands, compared to its average volume of 352,250. Haemonetics Corporation has a one year low of $36.44 and a one year high of $58.23. The firm has a market cap of $3,062.93, a PE ratio of 35.58, a P/E/G ratio of 4.36 and a beta of 0.91. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.51.

Haemonetics Corporation (NYSE:HAE) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.07. Haemonetics Corporation had a net margin of 0.50% and a return on equity of 11.16%. The company had revenue of $225.40 million for the quarter, compared to analysts’ expectations of $219.12 million. During the same period last year, the company earned $0.38 EPS. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. equities research analysts predict that Haemonetics Corporation will post 1.7 earnings per share for the current fiscal year.

Haemonetics Corporation Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.